Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Polymyalgia Rheumatica Rapid Symptom Improvement After Glucose Is Controlled

Linda Carroll (with a commentary from rheumatologist Eric Matteson, MD)  |  September 21, 2020

(Reuters Health)—In a case series report, researchers describe rapid symptom improvement in three patients with polymyalgia rheumatica (PMR) when high glucose levels were brought down.

After glucose was controlled, patients experienced improvement in both symptoms and laboratory measures of PMR without glucocorticoid administration or an increase in glucocorticoid dosage, according to the report in the Annals of Internal Medicine.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“These findings were unexpected and are remarkable,” write the authors, led by Dr. Ken Yoshida of The Jikei University School of Medicine, Tokyo. “We believe that coincidental improvement is an unlikely explanation for these cases.”

PMR is a chronic inflammatory condition affecting elderly persons, the authors note in their report, and is characterized by severe pain and stiffness, mostly in the shoulders, upper arms, and pelvic girdle.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers had no explanation for why controlling glucose levels may improve symptoms, but suggested that more research is in order.

“Treating PMR with glucocorticoid therapy is problematic,” the authors write. “Most patients require at least one to two years of treatment, and too many patients develop adverse effects, such as diabetes mellitus, osteoporosis and hypertension. Therefore, we propose that a randomized controlled trial be considered to determine whether improved glycemic control, perhaps with meglitinide, may allow patients with type 2 diabetes and PMR to avoid glucocorticoid treatment.”

The first case described by the researchers was a 68-year-old man with bilateral shoulder pain and morning stiffness. The patient, who fulfilled the 2012 EULAR/ACR provisional criteria for PMR had been taking NSAIDs for six weeks and had been receiving metformin to treat type 2 diabetes for five years. His labs showed: C-reactive protein (CRP) level, 62.9 mg/L (normal; <1.4 mg/L); hemoglobin mA1c (HbA1c) concentration, 7.9%; and fasting plasma glucose level, 8.88 mmol/L (160 mg/dL).

Before prescribing glucocorticoids, the researchers opted to first address his elevated glucose level by changing some of his antidiabetic medications and adding repaglinide, which improved his glycemic control. His PMR symptoms and laboratory findings improved considerably after just one week on the new regime and the biceps tenosynovitis initially detected on ultrasonography gradually resolved during the following year.

The second case involved a 72-year-old woman with bilateral shoulder pain, morning stiffness, bilateral hip pain and restricted hip mobility. She had been prescribed prednisolone, which did improve her symptoms, but when the dosage was tapered, the symptoms returned. When the researchers first saw her, she had a CRP level of 42.7 mg/L; an HbA1c concentration of 11.7%; and a postprandial glucose level of 18.6 mmol/L (335 mg/dL).

Page: 1 2 3 | Single Page
Share: 

Filed under:Uncategorized Tagged with:diabetesglucosePolymyalgia Rheumaticatype II diabetes

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

    How to Manage Polymyalgia Rheumatica

    December 16, 2015

    Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences